Epigenomics AG

EANS-Adhoc: Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics AG: Notice of Loss pursuant to § 92 par. 1 AktG

  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
other/Company Information/molecular diagnostics

Not for distribution in the United States

Berlin, Germany, December 21, 2012 - The Executive Board of Epigenomics AG
(ISIN: E000A1K0516) notifies that during the preparation of the annual financial
statements pursuant to German GAAP (HGB) accounting, according to its best
judgment a cumulative loss of more than half of the nominal share capital of the
company has been incurred. This is mainly attributable to budgeted losses from
regular business operations but as well to higher than expected expenses in
connection with the recently completed clinical study. 

The Executive Board is actively reviewing different measures to compensate for
the loss of half of the nominal share capital. The planned rights issue in
January 2013 as announced previously on December 20, 2012 is part of the
measures, which aim at improving the Company's equity and liquidity.

Pursuant to Sec. 92 par. 1 German Stock Corporation Act ("Aktiengesetz"), a loss
amounting to half of the nominal share capital triggers the statutory obligation
to summon a general meeting of shareholders without undue delay. The Executive
Board will therefore invite to an extraordinary general meeting in due course.
In this meeting, the Executive Board will notify the loss of half of the nominal
share capital and outline the situation of the company. An invitation including
an agenda to the extraordinary general meeting will be provided in due time and

- End of Ad hoc -

Contact Epigenomics AG
Antje Zeise CIRO
Manager IR | PR 
Epigenomics AG 
Phone: +49 (0) 30 24345 386 

Legal disclaimers. This communication expressly or implicitly contains certain
forward-looking statements concerning Epigenomics AG and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors which could cause the actual results, financial condition, performance
or achievements of Epigenomics AG to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication as of
this date and does not undertake to update any forward-looking statements
contained herein as a result of new information, future events or otherwise.

Further inquiry note:
Antje Zeise | CIRO 
Manager IR/PR 
Epigenomics AG
Tel: +49 30 24345 386

end of announcement                               euro adhoc 

issuer:      Epigenomics AG
             Kleine Präsidentenstraße 1
             D-10178 Berlin
phone:       +49 30 24345-0
FAX:         +49 30 24345-555
mail:     ir@epigenomics.com
WWW:      http://www.epigenomics.com
sector:      Biotechnology
ISIN:        DE000A1K0516
indexes:     Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
             regulated dealing/prime standard: Frankfurt 
language:   English

Weitere Meldungen: Epigenomics AG

Das könnte Sie auch interessieren: